Ezh2- fgfr inhibition in cancer
AssigneeStichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
InventorsAntonius Jozef Maria BERNS, Jitendra BADHAI, Maarten Matthijs Sharif VAN LOHUIZEN
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination of a FGFR inhibitor and an EZH2 inhibitor for use in a method of treating a patient suffering from a BRCA1-associated protein 1 (BAP1) negative cancer. The invention further relates to a pharmaceutical preparation, comprising a FGFR inhibitor and an EZH2 inhibitor, to the use of said pharmaceutical preparation in a method of treating BAP1-negative cancer, to methods of identifying a patient with cancer, who is eligible for treatment with a combination of a FGFR inhibitor and an EZH2 inhibitor, and to a mouse model for mesothelioma.
Claims19
A method of treating a patient suffering from a BRCA1-associated protein 1 (BAP1) negative cancer, the method comprising providing the patient with a combination of a FGFR inhibitor and an EZH2 inhibitor.
A pharmaceutical preparation, comprising a FGFR inhibitor and an EZH2 inhibitor.
A method of identifying a patient with cancer, especially mesothelioma, eligible for treatment with a combination of a FGFR inhibitor and an EZH2 inhibitor, comprising testing a biological sample comprising cancer cells from the patient for the presence of a mutation in BAP1 and/or loss of BAP1, wherein the patient is eligible for treatment with said combination if said tumor cells in said sample test positive for a mutation in BAP1.
A mouse model for mesothelioma, comprising knock-out alleles of Cdkn2a and Cdkn2b, and conditional knockout alleles of Bap1, Nf2 and p19Arf that can be activated at least in the mesothelial lining of the thoracic cavity.
Dependencies are inferred from the claim text.